Skip to search formSkip to main contentSkip to account menu

Humira

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Quality by design (QbD) is an efficient but challenging approach for the development of biosimilar due to the complex… 
2019
2019
  • Lisa Urquhart
  • Nature Reviews Drug Discovery
  • 2019
  • Corpus ID: 87739243
the biggestselling drug list again in 2018, it is hard to see where any challenger might come from to snatch the autoimmune… 
Highly Cited
2018
Highly Cited
2018
Objective To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira. Methods Patients with… 
2017
2017
ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities… 
2017
2017
AIMS To compare the pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a biosimilar of adalimumab, with… 
Highly Cited
2016
Highly Cited
2016
In this study, efficacy, tolerability and safety of biosimilar adalimumab (Exemptia; Zydus Cadila) was compared with reference… 
2016
2016
Aims The aim of the study was to compare the pharmacokinetics (PK), safety and tolerability of the proposed adalimumab biosimilar… 
Review
2012
Review
2012
Increasing evidence from epidemiological, preclinical and clinical studies suggests that dysregulated inflammatory response plays… 
2012
2012
Human embryos develop at varying rates in culture, with only a fraction of the eggs retrieved developing to ‘transfer quality… 
2004
2004
FDA-Approved Indications  Moderately to severely active rheumatoid arthritis (RA)  Moderately to severely active polyarticular…